Landry Robert E's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Dec 14, 2021
- Accession no.
- 0001883850-21-000028
- Filed
- Dec 14, 2021
- Trade date
- Dec 10-13, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $76.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Landry Robert ECIK 0001585160 | Officer (EVP Finance CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2021 | Common Stock | MOption exerciseAcquired | +1,500 | $555.67 | +$833,505 | 31,457 | Direct | |
| Dec 10, 2021 | Common Stock | FTax withholdingDisposed | −1,384 | $664.34 | −$919,446.56 | 30,073 | Direct | |
| Dec 11, 2021 | Common Stock | FTax withholdingDisposed | −697 | $664.34 | −$463,044.98 | 29,376 | Direct | |
| Dec 13, 2021 | Common Stock | SSaleDisposed | −116 | $662.50 | −$76,850 | 29,260 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 10, 2021 | Common Stock | MOption exerciseDisposed | −1,500 | $0.00 | $0 | 2,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.